# Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

> **NCT04272645** · PHASE2 · WITHDRAWN · sponsor: **University of Michigan Rogel Cancer Center**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abemaciclib 200 MG
- **DRUG:** Atezolizumab 1200 MG in 20 ML Injection
- **DRUG:** Abemaciclib 150 MG

## Key facts

- **NCT ID:** NCT04272645
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Coordinating site change
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04272645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04272645, "Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04272645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*